Panel interviews can play a major role in getting jobs. Two career coaches discuss what to do before and during the interview, including identifying how to differentiate yourself, engaging in true conversations and not overlooking a key panel member.

Original title: “Winning the room: how to ace panel interviews”

Sanofi’s investment will support a Canadian site’s efforts to apply AI to drug production, while Amgen has unveiled the second expansion of its Puerto Rico plant in quick succession.

Original title: “Amgen, Sanofi commit nearly $600M to North American expansions”

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

Original title: “Novo hikes guidance on Wegovy pill’s fast sales start”

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

Original title: “Avalo shares spike on skin drug data; BioNTech to cut staff”

Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.

Original title: “Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales”

First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad’s controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency’s first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.

Original title: “Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening”

In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending cold emails to investors and learning to address leadership weaknesses.

Original title: “Founders face pressure from all sides as biotech crawls toward recovery”

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OncoVanta Therapeutics, Inc. ("OncoVanta"), a company located in Hagerstown, Maryland, the United States of America.

Original title: “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer”

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Original title: “Pfizer is a 2029 story but Q126 lays foundation for growth”

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Original title: “BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs”

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.

Original title: “Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat”

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.

Original title: “Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead”

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

Original title: “Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution”

The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.

Original title: “Foundayo’s liver failure blip weighs down Lilly shares but analysts unconcerned”

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.

Original title: “Cytospire hauls in $83M for a new type of T cell engager”